Genomic Medicine Institute Adds Seven Additional Illumina Genome Analyzers to Expand Capacity for Asian 100 Genome Project

SEOUL, Korea–Illumina (NASDAQ:ILMN) today announced that the Genomic Medicine Institute (GMI) at Seoul National University College of Medicine in Korea, purchased seven additional Illumina Genome AnalyzerIIx sequencing systems, expanding the capacity of their recently established Asian Genome Center to 10 Illumina sequencing systems.

“GMI’s decision to add seven additional Genome Analyzers is further validation that our sequencing platform is delivering leading performance with its unmatched rate of daily output, ease of use and proven paired-end sequencing capabilities,” said Tim Orpin, general manager of Illumina’s Asia Pacific Region.

Dr. Jeong-Sun Seo, director of the Genomic Medicine Institute, and his team, have completed a deep sequencing project of the Korean genome and the work was published online in Nature July 8, 2009. “This publication demonstrates the global competitiveness of GMI’s technological capabilities and provides a practical example of Korean bio-medical excellence,” said Dr. Seo.

GMI is the second largest Genome Center in Asia and the largest center that focuses exclusively on human genome analysis and its clinical application in Asia. As part of the Asian 100 Genome Project, GMI plans to complete the whole genome analysis of 100 Asian individuals by 2012 and establish an Asian Genome Database with comprehensive genome information specifically targeting Asian populations.

About the Illumina Genome Analyzer

Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. Generating over 20 Gigabases of sequence data, the Genome Analyzer offers the highest rate of daily output and the simplest and most user-friendly workflow. The Genome Analyzer also offers the broadest set of supported applications, including those used to profile and discover novel transcripts, to create a high-resolution genome-wide map of DNA-protein binding sites and to sequence entire human genomes to greater than 30x coverage. For more information about the Genome Analyzer and to read what customers are doing with Illumina’s sequencing technology, please visit https://www.illumina.com/sequencing.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.